Caplin Point Laboratories Limited
Regd. office: Ashvich Tower, 3rd Floor,
No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.
Phone : +91 44 24968000 / +91 80127 72888 / +91 44 71148000
E-mail : info@caplinpoint.net / Website : www.caplinpoint.net
CIN : L24231TN1990PLC019053

06th January, 2025

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G,Bandra Kurla Complex,
Bandra (E),Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Press Release – Receipt of Establishment Inspection Report

Attaching herewith a Press Release regarding receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) with Zero 483 observations for the unannounced inspection conducted at Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi between August 05th and 09th, 2024.

Kindly take the same on your records.

Sincerely Yours

For Caplin Point Laboratories Limited

VENKATRAM GANAPATHISUBRAMANIAN
Digitally signed by VENKATRAM GANAPATHISUBRAMANIAN
Date: 2025.01.06 18:11:36 +05'30'

Venkatram G
General Counsel & Company Secretary
Membership No A23989

Press Release

CAPLIN POINT RECEIVES ESTABLISHMENT INSPECTION REPORT (EIR) FROM FDA WITH ZERO 483 OBSERVATIONS

Chennai, January 06, 2025: Caplin Point Laboratories Ltd. ("Caplin Point" or the "Company") (BSE: 524742 | NSE: CAPLIPOINT), announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the recent inspection conducted at Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi. The unannounced USFDA inspection was conducted between August 5th and 9th, 2024 and was concluded with Zero 483 observations, reflecting the company's commitment to maintaining the highest standards of quality and compliance.

This press release follows the intimation made to the Stock Exchanges on August 9th, 2024 immediately upon completion of the inspection about its outcome. The inspection, which is a routine part of the FDA's regulatory oversight, evaluates compliance with Good Manufacturing Practices and other regulatory requirements.

About Caplin Steriles Limited

Caplin Steriles Limited, a Subsidiary of Caplin Point Laboratories Limited, is a fast growing sterile product manufacturing company that is approved by several regulatory agencies such as US FDA, EU-GMP, ANVISA and INVIMA. Caplin Steriles Limited, has developed and filed 45 ANDAs in USA on its own and with partners, with 31 approvals so far. The Company is also working on a portfolio of 40+ simple and complex Injectable and Ophthalmic products, that it intends to file over the next 4 years. The company also has multiple products filed with several approvals in non-US markets such as Mexico, Australia, Canada, South Africa etc

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. Caplin Point is one of the few companies to show consistent high-quality growth in cashflows, Profitability and Revenues over the last 15 years.

Caplin Point has appeared on **Forbes "Asia's 200 Best Under a Billion"** list for an unprecedented 7th time in the last 10 years, and was awarded "The Emerging Company of 2018" and "Business Excellence Award for 2019" by Economic Times.

CAUTIONARY STATEMENT:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Caplin Point Laboratories Ltd and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Caplin Point Laboratories Ltd, nor our directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.

For details, please contact:

Investor Relations at Caplin	**Registered Office**
Mr G Venkatram (General Counsel & Company Secretary) Tel: +91 44 24968000 investor@caplinpoint.net **Churchgate Partners** Anvita Raghuram / Rajiv Pandya +91 22 6169 5988 caplinpoint@churchgatepartners.com	Caplin Point Laboratories Limited 3rd Floor, Ashvich Tower, No. 3, Developed Plots Industrial Estate, Perungudi, Chennai – 600 096, Tamil Nadu, INDIA. Tel: +91 44 2496 8000 CIN: L24231TN1990PLC019053 ISIN: INE475E01026 NSE Code: CAPLIPOINT BSE CODE: 524742 Website: www.caplinpoint.net